These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27552096)

  • 1. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
    Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
    Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
    Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
    Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
    BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
    Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
    Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
    Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
    Sieuwerts AM; Schrijver WA; Dalm SU; de Weerd V; Moelans CB; Ter Hoeve N; van Diest PJ; Martens JW; van Deurzen CH
    PLoS One; 2017; 12(1):e0171343. PubMed ID: 28141868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
    Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
    Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
    Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
    Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
    Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
    Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
    Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
    Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
    Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
    Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
    PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Kiiski JI; Fagerholm R; Tervasmäki A; Pelttari LM; Khan S; Jamshidi M; Mantere T; Pylkäs K; Bartek J; Bartkova J; Mannermaa A; Tengström M; Kosma VM; Winqvist R; Kallioniemi A; Aittomäki K; Blomqvist C; Nevanlinna H
    Int J Cancer; 2016 Dec; 139(12):2760-2770. PubMed ID: 27542569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
    Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
    Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
    Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.